The tariff classification of Deucravacitinib Tablets in dosage form, from Ireland

N326052 June 9, 2022 CLA-2-30:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 3004.90.9215 Craig A. Lewis, Esq. Hogan Lovells US LLP 555 Thirteenth Street, N.W. Washington, D.C. 20004 RE: The tariff classification of Deucravacitinib Tablets in dosage form, from Ireland Dear Mr. Lewis: In your letter dated May 10, 2022, on behalf of E. R. Squibb & Sons, LLC., a Bristol-Myers Squibb (“BMS”) Company, you requested a tariff classification ruling. Deucravacitinib, imported in 3 mg, 6 mg, and 12 mg tablets, is an oral, selective tyrosine kinase 2 (TYK2) inhibitor. In your letter, you stated Deucravacitinib is currently undergoing evaluation as a treatment for a variety of autoimmune diseases, including moderate to severe plaque psoriasis. The applicable subheading for the Deucravacitinib Tablets in dosage form will be 3004.90.9215, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at judy.h.lee@cbp.dhs.gov. Sincerely, Steven A. Mack Director National Commodity Specialist Division